ACG IBD 2016

ACG IBD 2016 Symposium

PROGRAM Information

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with inflammatory bowel disease (IBD).

Educational Objectives

After Upon completing this program, participants should be better able to:

Personalize treatment plans for patients based on risk of aggressive disease

Describe recent advances with current and emerging IBD therapies

Identify proactively patients with iron deficiency anemia

Differentiate among various oral and IV iron formulations and incorporate them effectively into clinical practice


Americans with Disabilities Act:

The event staff will be glad to assist you with any special needs (ie, physical, dietary). Please contact us prior to the event at 1-877-782-4532.

For more information, email us at info@GiHealthFoundation.org, or call 1-877-782-4532.

A Gi Health Foundation Special event

(select a speaker to view their bio and disclosure)

SATURDAY, OCTOBER 15, 2016

5:30 PM Registration Dinner
6:00-7:30 PM CME Symposium

On-site registration is available.
Space is limited; please arrive by 5:30 PM

THE VENETIAN LAS VEGAS

The Venetian Ballroom GH

Agenda

5:30 PMRegistration/Seating/Dinner

6:00 PMWelcome and Introduction

6:05 PMPatient Case 1: Mild to Moderate Crohn's Disease (CD)

6:55 PMPatient Case 2: Moderate to Severe CD

7:10 PMUnmet Needs in IBD: Reviewing the Evidence for Novel Therapeutics

7:20 PMPanel Discussion and Q&A

7:30 PMClosing Remarks

This event is neither sponsored by nor endorsed by ACG.
Supported by educational grants from American Regent, Inc., and Janssen Biotech, Inc.

Provided by:

David G. Binion, MD. AGAF, FACG

David G. Binion, MD, is a Professor of Medicine and Professor of Clinical and Translational Science in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, USA. He also serves as Co-Director of the Inflammatory Bowel Disease Center and Director of Translational Inflammatory Bowel Disease Research at University of Pittsburgh Medical Center (UPMC), where he is also Director of the Nutrition Support Service. After graduating from Harvard College in Cambridge, Massachusetts, he completed his MD at the State University of New York in Buffalo and his internship and residency at Rhode Island Hospital, Brown University Program in Medicine in Providence, Rhode Island. After completing a gastroenterology fellowship at the University Hospitals of Cleveland, Dr. Binion was a Research Associate in mucosal immunology at Case Western Reserve University, also in Cleveland, where he also completed a postdoctoral fellowship in vascular biology at the Cleveland Clinic Foundation. Dr. Binion joined the staff at the Medical College of Wisconsin in Milwaukee, Wisconsin as an Assistant Professor of Medicine in 1997, where he rose to the rank of Professor of Medicine in 2007. Dr. Binion founded and directed the Inflammatory Bowel Disease Program at the Medical College of Wisconsin before joining the University of Pittsburgh in 2008.

Dr. Binion's research interests focus on the molecular and cellular mechanisms of human inflammatory bowel disease and Clostridium difficile infection. His recent investigation has focused on the heterogeneity of IBD patient subgroups and characterization of clinical trajectories with the goal of implementing precision treatment and personalized medicine. He has published over 150 refereed articles, reviews and book chapters, and has authored over 250 scientific abstracts presented at national and international congresses.

Dr. Binion has received the Premier Physician Award from the Crohn's and Colitis Foundation of America, and is a Fellow of the American College of Gastroenterology and the American Gastroenterological Association.

Speaker Disclosures

Grant Recipient: Janssen and Merck

This event is neither sponsored by nor endorsed by ACG.
Supported by educational grants from American Regent, Inc., and Janssen Biotech, Inc.

Provided by:

Gary R. Lichtenstein, MD

Gary R. Lichtenstein, MD, FACP, FACG, AGAF, is the director of the Inflammatory Bowel Disease Center and a professor of medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania.

Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in internal medicine at Duke University Medical Center, in Durham, North Carolina. He also served a fellowship in gastroenterology at the Hospital of the University of Pennsylvania of the University of Pennsylvania School of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn's disease, and he has received numerous research grants focusing on these areas. Dr. Lichtenstein has served as the national/ international principal investigator evaluating novel agents for therapeutic trials in the treatment of ulcerative colitis and Crohn's disease.

A Fellow of the American Gastroenterological Association (AGA), the American College of Physicians, and the American College of Gastroenterology (ACG), Dr. Lichtenstein has been listed in "Best Doctors in America" (inflammatory bowel disease), and he has served as medical secretary for the American Board of Internal Medicine, Gastroenterology Section. He holds membership and committee positions in many professional societies at a national level, including the AGA, where he has served as vice-chair of the clinical practice committee and practice economics committee and as chair of the clinical practice committee; the American Society for Gastrointestinal Endoscopy, where he has served on the committee on training; and the ACG, where he has served on the education committee, programs committee, and the nominations committee as well as recently serving as a member of the research committee. He has also been the chair of the abstract review committee for inflammatory bowel disease for the ACG. He is a member of the Crohn's and Colitis Foundation of America (CCFA) where he served at the national level as the chair of the membership committee of the Clinical Research Alliance, on the national grants review committee, and on the national physician education committee. In addition, he is a longstanding member of the American College of Physicians and the American Medical Association.

Dr. Lichtenstein has received numerous awards, including the award for the top specialist in the University of Pennsylvania Health System, the Louis A. Duhring Award. He is the recipient of the Christina and Marie Lindback Award, the top teaching award at the University of Pennsylvania and the medical school teaching award, the Penn Pearls Award. He has received the Department of Medicine Housestaff teaching award, the Donald B. Martin Teaching Award and the Gastroenterology Division teaching award, the Sidney Cohen Teaching Award. He is listed in "The Best Doctors in America" (inflammatory bowel disease) and in Philadelphia Magazine as being among the top gastroenterologists for the elderly in Philadelphia and also among the top gastroenterologists in Philadelphia (Special Focus: Inflammatory Bowel Disease). He is also the recipient of the CCFA Physician of the Year Award: Philadelphia and Delaware Valley Chapters.

In addition to having served on the editorial board of the journals Gastroenterology, the American Journal of Gastroenterology, Inflammatory Bowel Diseases, the World Journal of Gastroenterology, and Digestive Diseases and Sciences, Dr. Lichtenstein has served as a former writer of selected summaries in the journal Gastroenterology, as the section editor of selected summaries, and the section editor of print and media review in gastroenterology for a 5-year term. He also has served and currently serves as a reviewer for such journals as the New England Journal of Medicine, Gastroenterology, The Lancet, the Annals of Internal Medicine, Gut, the Journal of Parenteral and Enteral Nutrition, the American Journal of Gastroenterology, the World Journal of Gastroenterology, and the Journal of Clinical Gastroenterology. He is executive editor of a newly PubMed-indexed journal Gastroenterology & Hepatology, and serves as associate editor of Therapeutic Advances in Gastroenterology, The Physician and Sportsmedicine, and the Journal of Clinical Investigation. He is currently assistant editor-in-chief of the World Journal of Gastroenterology. An invited lecturer at local, national, and international levels, Dr. Lichtenstein is the author or coauthor of more than 250 peer-reviewed primary articles, chapters, letters, and editorials. He has presented over 250 abstracts and edited 18 books. He has lectured at a national and international level at more than 300 invited conferences, symposia, and institutional grand rounds.

Speaker Disclosures

Author: McMahon Publishing, UpToDate

Book Royalty: SLACK, Inc.

Consultant: Abbott /AbbVie Inc., Actavis, Alaven Pharmaceutical LLC, Ferring B.V., Hospira, Inc., Janssen Products LP, Luitpold Pharmaceuticals, Inc./American Regent, Inc., Pfizer Inc., Prometheus, Romark Laboratories, L.C., Salix Pharmaceuticals, Inc., Santarus Inc., Shire, Takeda Pharmaceutical Company Limited, UCB S.A., Warner Chilcott Pharmaceuticals

Editor: Gastroenterology & Hepatology (Gastro-Hep Communications), Clinical Advances in Gastroenterology, Springer Science+Business Media

Funding to University of PA (IBD Fellow Education): Janssen Products LP

Grant: Warner Chilcott Pharmaceuticals

Honoraria: Clinical Advances in Gastroenterology, Gastroenterology & Hepatology (Gastro-Hep Communications), Ironwood Pharmaceuticals Inc., Luitpold Pharmaceuticals, Inc./American Regent, Inc., McMahon Publishing, Springer Science+Business Media, UpToDate

Research: Ferring B.V., Janssen Products LP, Prometheus, Salix Pharmaceuticals, Inc., Santarus Inc., Shire, UCB S.A., Warner Chilcott Pharmaceuticals

This event is neither sponsored by nor endorsed by ACG.
Supported by educational grants from American Regent, Inc., and Janssen Biotech, Inc.

Provided by:

Stephen B. Hanauer, MD

Stephen B. Hanauer, MD, is currently president of the American College of Gastroenterology. He completed a medical degree, with honors, at the University of Illinois in Chicago. His postdoctoral training included an internship and residency in internal medicine as well as a fellowship in gastroenterology at the University of Chicago. He rose through academic ranks to become professor of medicine and subsequently was awarded the Joseph B. Kirsner Chair in Medicine and designated chief of the Section of Gastroenterology, Hepatology, and Nutrition, where he served from 2000 to 2014. He was recruited as the medical director of the Digestive Health Center at Northwestern Medicine and is the Clifford Joseph Barborka Professor of Medicine in the Northwestern Feinberg School of Medicine as of January 1, 2014.

Dr. Hanauer is board certified in internal medicine and gastroenterology by the American Board of Internal Medicine and the American Board of Gastroenterology, respectively. He holds membership in several professional societies and is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology, and the American College of Physicians. In connection with the AGA, Dr. Hanauer served as chair for the Inflammation, Immunology, and Inflammatory Bowel Disease Section and the Clinical Practice Section and subsequently served as councilor for clinical research on the AGA Governing Board. He is a prior member of the Specialty Board of the American Board of Internal Medicine. Among his many honors, Dr. Hanauer received the AGA Fiterman Foundation Joseph B. Kirsner Award in Gastroenterology in 2001 and the Janssen Award for Clinical Excellence in 2004. He has served as a member and chair of the US Food and Drug Administration Advisory Panel for Gastrointestinal Disorders and is a member and former-chairman of the International Organization for Inflammatory Bowel Disease.

Dr. Hanauer has authored hundreds of peer-reviewed journal articles, books and book chapters, abstracts, monographs, and editorials. He is ex-editor-in-chief of Nature Clinical Practice Gastroenterology & Hepatology and currently serves as associate editor (IBD) of Clinical Gastroenterology and Hepatology. He is also a member of the editorial boards of numerous journals, including the American Journal of Gastroenterology, and Inflammatory Bowel Diseases.

Speaker Disclosures

Clinical Research: AbbVie Inc., Amgen Inc., Celgene, Janssen Products, LP, Eli Lilly and Company, Luitpold Pharmaceuticals, Inc./American Regent, Inc., Novo Nordisk, Pfizer Inc., Prometheus, Receptos, Takeda Pharmaceutical Company Limited, UCB S.A.

Consultant: AbbVie Inc., Activis, Amgen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene, Celltrion Inc., Ferring B.V., Hospira, Inc., Janssen Products, LP, Eli Lilly and Company, Luitpold Pharmaceuticals, Inc./American Regent, Inc., Novo Nordisk, Pfizer Inc., Prometheus, Receptos, Salix Pharmaceuticals, Inc., Shire, Takeda Pharmaceutical Company Limited, Theradiag, UCB S.A.

DSMB: Bristol-Myers Squibb

Speaker: AbbVie Inc., Janssen Products, LP, Takeda Pharmaceutical Company Limited

This event is neither sponsored by nor endorsed by ACG.
Supported by educational grants from American Regent, Inc., and Janssen Biotech, Inc.

Provided by:

William J. Sandborn, MD

Dr. Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda, California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota, in 1993. From 1993 to 2010, he was on the faculty of the Mayo Clinic, rising to professor of medicine, vice chairman of the Division of Gastroenterology and Hepatology, and associate dean of research for intellectual property and industry relations.

In 2011, Dr. Sandborn became professor of medicine and adjunct professor of surgery at the University of California (UC), San Diego, and director of the IBD Center and chief of the Division of Gastroenterology for the UC San Diego Health System. Dr. Sandborn has published over 541 peer-reviewed articles, including articles in the New England Journal of Medicine, The Lancet, the Journal of the American Medical Association, the Annals of Internal Medicine, and Gastroenterology. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease.

Speaker Disclosures

Grant Recipient: AbbVie Inc., Amgen Inc., Celgene, Genentech, Inc., Janssen Products, LP, Pfizer Inc., Takeda Pharmaceuticals U.S.A., Inc.

Consultant: AbbVie Inc., Amgen Inc., Celgene, Genentech, Inc., Janssen Products, LP, Pfizer Inc., Takeda Pharmaceuticals U.S.A., Inc., UCB, Inc.

This event is neither sponsored by nor endorsed by ACG.
Supported by educational grants from American Regent, Inc., and Janssen Biotech, Inc.

Provided by:

Corey A. Siegel, MD, MS

Corey A. Siegel, MD, MS, is the director of the Inflammatory Bowel Disease (IBD) Center at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, and an associate professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts in 1998. He completed his residency in internal medicine at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. Dr. Siegel served as chief medical resident at Dartmouth from 2001-2002, where he also completed a fellowship in gastroenterology. From 2004-2005, he completed a fellowship in inflammatory bowel disease at Massachusetts General Hospital in Boston, Massachusetts.

Dr. Siegel's research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn's disease, creating tools to facilitate shared decision making, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, and the Crohn's and Colitis Foundation of America (CCFA) for this work. He has lectured nationally and internationally, and published numerous journal articles and book chapters on this and other topics in IBD. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. He has served as the co-chairperson of the CCFA Professional Education Committee, and is currently the chair of the CCFA's Quality of Care Program. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013. He is on the editorial board for Clinical Gastroenterology and Hepatology and Alimentary Pharmacology & Therapeutics, and serves as a reviewer for The American Journal of Gastroenterology, Clinical Gastroenterology and Hepatology, Journal of Crohn's and Colitis, Inflammatory Bowel Diseases, the Cochrane Collaboration, and Gastroenterology. He lives in Hanover, New Hampshire with his wife and three boys.

Speaker Disclosures

Grants/Research Support: CCFA, AHRQ (1R01HS021747-01), AbbVie, Janssen, Salix, Takeda, UCB

Advisory Board Membership: AbbVie, Amgen, Lilly, Janssen, Salix, Pfizer, Prometheus, Takeda, Theradiag, UCB

Other Financial Material Support: AbbVie, Janssen, Takeda

This event is neither sponsored by nor endorsed by ACG.
Supported by educational grants from American Regent, Inc., and Janssen Biotech, Inc.

Provided by: